APTIVUS Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Aptivus, and when can generic versions of Aptivus launch?
Aptivus is a drug marketed by Boehringer Ingelheim and is included in two NDAs.
The generic ingredient in APTIVUS is tipranavir. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tipranavir profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for APTIVUS?
- What are the global sales for APTIVUS?
- What is Average Wholesale Price for APTIVUS?
Summary for APTIVUS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 61 |
| Clinical Trials: | 7 |
| Patent Applications: | 5,341 |
| Drug Prices: | Drug price information for APTIVUS |
| What excipients (inactive ingredients) are in APTIVUS? | APTIVUS excipients list |
| DailyMed Link: | APTIVUS at DailyMed |
Recent Clinical Trials for APTIVUS
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Boehringer Ingelheim | Phase 3 |
| National Institutes of Health (NIH) | Phase 2/Phase 3 |
| National Institute of Mental Health (NIMH) | Phase 2/Phase 3 |
Pharmacology for APTIVUS
| Drug Class | Protease Inhibitor |
| Mechanism of Action | HIV Protease Inhibitors |
US Patents and Regulatory Information for APTIVUS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | APTIVUS | tipranavir | CAPSULE;ORAL | 021814-001 | Jun 22, 2005 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Boehringer Ingelheim | APTIVUS | tipranavir | SOLUTION;ORAL | 022292-001 | Jun 23, 2008 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for APTIVUS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | APTIVUS | tipranavir | CAPSULE;ORAL | 021814-001 | Jun 22, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| Boehringer Ingelheim | APTIVUS | tipranavir | CAPSULE;ORAL | 021814-001 | Jun 22, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| Boehringer Ingelheim | APTIVUS | tipranavir | SOLUTION;ORAL | 022292-001 | Jun 23, 2008 | ⤷ Sign Up | ⤷ Sign Up |
| Boehringer Ingelheim | APTIVUS | tipranavir | SOLUTION;ORAL | 022292-001 | Jun 23, 2008 | ⤷ Sign Up | ⤷ Sign Up |
| Boehringer Ingelheim | APTIVUS | tipranavir | SOLUTION;ORAL | 022292-001 | Jun 23, 2008 | ⤷ Sign Up | ⤷ Sign Up |
| Boehringer Ingelheim | APTIVUS | tipranavir | CAPSULE;ORAL | 021814-001 | Jun 22, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| Boehringer Ingelheim | APTIVUS | tipranavir | CAPSULE;ORAL | 021814-001 | Jun 22, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for APTIVUS
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim International GmbH | Aptivus | tipranavir | EMEA/H/C/000631 Aptivus, co-administered with low-dose ritonavir, is indicated for combination antiretroviral treatment of HIV-1 infection in highly pretreated adults and adolescents 12 years of age or older with virus resistant to multiple protease inhibitors.Aptivus should only be used as part of an active combination antiretroviral regimen in patients with no other therapeutic options.This indication is based on the results of two phase-III studies, performed in highly pretreated adult patients (median number of 12 prior antiretroviral agents) with virus resistant to protease inhibitors and of one phase-II study investigating pharmacokinetics, safety and efficacy of Aptivus in mostly treatment-experienced adolescent patients aged 12 to 18 years.In deciding to initiate treatment with Aptivus, co-administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of Aptivus. Initiation of treatment should take into account the combinations of mutations which may negatively impact the virological response to Aptivus, co-administered with low-dose ritonavir. |
Authorised | no | no | no | 2005-10-25 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for APTIVUS
See the table below for patents covering APTIVUS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 8573998 | ⤷ Sign Up | |
| Slovenia | 0989851 | ⤷ Sign Up | |
| Germany | 69823663 | ⤷ Sign Up | |
| Poland | 192080 | ⤷ Sign Up | |
| Poland | 338334 | ⤷ Sign Up | |
| Slovenia | 0999826 | ⤷ Sign Up | |
| Hong Kong | 1040625 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for APTIVUS
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0758327 | C300216 | Netherlands | ⤷ Sign Up | PRODUCT NAME: TIPRANAVIR, DESGEWENST IN DE VORM VAN EEN; REGISTRATION NO/DATE: EU/1/05/315/001 20051025 |
| 0758327 | SPC/GB06/009 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: (R-(R*,R*))-N-(3-(1-(5,6-DIHYDRO-4-HYDROXY-2-OXO-6-(2-PHENYLETHYL)-6-PROPYL-2H-PYRAN-3-YL)PROPYL)PHENYL)-5-(TRIFLUOROMETHYL)-2-PYRIDINESULFONAMIDE OR A PHARMACEUTICAL SALT THEREOF = (TIPRANAVIR OR A PHARMACEUTICAL SALT THEREOF); REGISTERED: CH 57330 20050825; UK EU/1/05/315/001 20051025 |
| 0758327 | C00758327/01 | Switzerland | ⤷ Sign Up | FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH |
| 0758327 | CA 2005 00052 | Denmark | ⤷ Sign Up | |
| 0758327 | PA2005008 | Lithuania | ⤷ Sign Up | PRODCT NAME: TIPRANAVIRUM; REGISTRATION NO/DATE: EU/1/05/315/001 20051025 |
| 0758327 | 300216 | Netherlands | ⤷ Sign Up | 300216, 20150504, EXPIRES: 20200503 |
| 0758327 | SPC034/2005 | Ireland | ⤷ Sign Up | SPC034/2005: 20061023, EXPIRES: 20200503 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
